{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:01:04Z","timestamp":1790352064373,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"The Permanente Medical Group\u2019s Delivery Science and Applied Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Isotretinoin prescription for acne varies widely, partially due to inconsistent guidelines. This leaves physicians to rely on clinical judgement, experience and institutional practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We examined real-world isotretinoin prescribing patterns among dermatologists in a large healthcare system, focusing on dosing variability and predictors of total cumulative dosage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study at Kaiser Permanente Northern California (KPNC) included 9551 KPNC members aged 13\u201340\u2005years who received at least 1 isotretinoin prescription for acne between 1 January 2016 and 31 December 2022. The primary outcome was cumulative isotretinoin dose (mg kg\u22121). Secondary outcomes included starting and maximum daily doses, time to maximum dose, and total treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 9551 participants, most were &amp;lt; 18\u2005years old (5609, 59%), with an equal split between male and female patients (female: 4911, 51%). Common starting doses were 0.5\u20130.75\u2005mg kg\u22121 per day (4809 of 9326, 52%), with 35% reaching a maximum of 1\u20131.25\u2005mg kg\u22121 per day. The mean cumulative dose was 137\u2005mg kg\u22121 (SD 62.5), with 25% of patients receiving 120\u2013150\u2005mg kg\u22121. This is consistent with the 2016 American Academy of Dermatology guidelines. Doses &amp;gt; 175\u2005mg kg\u22121 were used in 25%. Significant predictors of higher cumulative dosing included female sex, younger age, prior antibiotic use and more acne-related visits. Additionally, Asian and White patients received significantly higher cumulative doses than Black patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights substantial variability in isotretinoin prescribing practices. Although medium-range cumulative doses aligned with previous guidelines, there was substantial variability in cumulative dosing. These findings highlight the need for comparative studies of alternative dosing strategies. More comprehensive guidelines incorporating alternative dosing models could optimize acne treatment and ensure equitable care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag225","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:41:58Z","timestamp":1780573318000},"page":"1874-1880","source":"Crossref","is-referenced-by-count":0,"title":["Variability and predictors of isotretinoin dosing in patients with acne: a retrospective cohort study"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7772-6055","authenticated-orcid":false,"given":"Noah M","family":"Contreras","sequence":"first","affiliation":[{"name":"Kaiser Permanente Bernard J. Tyson School of Medicine , Pasadena, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Division of Research, Northern California Kaiser Permanente , Oakland, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amara A","family":"Lieberman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Northern California Kaiser Permanente , San Jose, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Avins","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Bernard J. Tyson School of Medicine , Pasadena, CA ,","place":["USA"]},{"name":"Division of Research, Northern California Kaiser Permanente , Oakland, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Vanchinathan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Northern California Kaiser Permanente , San Jose, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2026092511030164700_llag225-B1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1087-0024.2003.09108.x","article-title":"Dermatologists and office-based care of dermatologic disease in the 21st century","volume":"9","author":"Stern","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2026092511030164700_llag225-B2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjd.12149","article-title":"Epidemiology of acne vulgaris","volume":"168","author":"Bhate","year":"2013","journal-title":"Br J Dermatol"},{"key":"2026092511030164700_llag225-B3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003495-198428010-00002","article-title":"Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders","volume":"28","author":"Ward","year":"1984","journal-title":"Drugs"},{"key":"2026092511030164700_llag225-B4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.det.2011.09.001","article-title":"Acne vulgaris: pathogenesis, treatment, and needs assessment","volume":"30","author":"Knutsen-Larson","year":"2012","journal-title":"Dermatol Clin"},{"key":"2026092511030164700_llag225-B5"},{"key":"2026092511030164700_llag225-B6","author":"Roche Laboratories"},{"key":"2026092511030164700_llag225-B7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/17512433.2020.1796637","article-title":"The use of isotretinoin for acne \u2013 an update on optimal dosing, surveillance, and adverse effects","volume":"13","author":"Bagatin","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026092511030164700_llag225-B8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/ijd.15089","article-title":"Isotretinoin in the management of acne vulgaris: practical prescribing","volume":"60","author":"Fallah","year":"2021","journal-title":"Int J Dermatol"},{"key":"2026092511030164700_llag225-B9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1365-4632.2011.05409.x","article-title":"High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life","volume":"51","author":"Cyrulnik","year":"2012","journal-title":"Int J Dermatol"},{"key":"2026092511030164700_llag225-B10","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/jamadermatol.2013.6746","article-title":"High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris","volume":"149","author":"Blasiak","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2026092511030164700_llag225-B11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2026092511030164700_llag225-B12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 1","key":"2026092511030164700_llag225-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04374.x","article-title":"European evidence-based (S3) guidelines for the treatment of acne","volume":"26","author":"Nast","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2 Suppl. 1","key":"2026092511030164700_llag225-B14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","article-title":"Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne","volume":"78","author":"Thiboutot","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026092511030164700_llag225-B15","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1111\/jdv.16430","article-title":"Comparison of guidelines and consensus articles on the management of patients with acne with oral isotretinoin","volume":"34","author":"Dessinioti","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092511030164700_llag225-B16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7812\/TPP\/22.172","article-title":"Comparing Kaiser Permanente members to the general population: implications for generalizability of research","volume":"27","author":"Davis","year":"2023","journal-title":"Perm J"},{"key":"2026092511030164700_llag225-B17","doi-asserted-by":"publisher","DOI":"10.13140\/RG.2.2.21338.35524","volume-title":"Similarity of adult Kaiser Permanente Members to the adult population in Kaiser Permanente\u2019s Northern California service area: comparisons based on the 2017\/2018 cycle of the California Health Interview Survey","author":"Gordon","year":"8, 2020"},{"key":"2026092511030164700_llag225-B18","author":"R Core Team"},{"key":"2026092511030164700_llag225-B19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamadermatol.2019.4818","article-title":"Association of race\/ethnicity and sex with differences in health care use and treatment for acne","volume":"156","author":"Barbieri","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026092511030164700_llag225-B20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00403-022-02394-4","article-title":"Gender differences in isotretinoin prescriptions during the COVID-19 pandemic at a U.S. academic medical center","volume":"315","author":"Duan","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2026092511030164700_llag225-B21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/pde.15394","article-title":"Gender disparities in isotretinoin prescribing patterns for pediatric patients before and during practice changes introduced by the COVID-19 pandemic","volume":"40","author":"Tan","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"2026092511030164700_llag225-B22","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1067\/S0190-9622(03)01584-6","article-title":"Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States?","volume":"49","author":"Fleischer","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2026092511030164700_llag225-B23","doi-asserted-by":"crossref","first-page":"e42883","DOI":"10.2196\/42883","article-title":"Prescribing patterns of oral antibiotics and isotretinoin for acne in a Colorado hospital system: retrospective cohort study","volume":"6","author":"Adelman","year":"2023","journal-title":"JMIR Dermatol"},{"key":"2026092511030164700_llag225-B24","doi-asserted-by":"crossref","first-page":"e0210445","DOI":"10.1371\/journal.pone.0210445","article-title":"Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era","volume":"14","author":"Charrow","year":"2019","journal-title":"PLOS ONE"},{"key":"2026092511030164700_llag225-B25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/ijd.16961","article-title":"Racial, ethnic, and biologic sex disparities in outpatient laboratory monitoring of isotretinoin use: a cross-sectional study","volume":"63","author":"Manoharan","year":"2024","journal-title":"Int J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag225\/68478813\/llag225.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1874\/68478813\/llag225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1874\/68478813\/llag225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:03:21Z","timestamp":1790348601000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/10\/1874\/8702777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag225","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,5]]}}}